Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Berkeley Lights Scoops Up IsoPlexis, Creating A Premier Functional Cell Biology Company

Published 22/12/2022, 12:37
© Reuters.  Berkeley Lights Scoops Up IsoPlexis, Creating A Premier Functional Cell Biology Company
BKGH
-
BKGFY
-
CELL
-
ISO
-

Benzinga -

  • Berkeley Lights Inc (NASDAQ: BLI) has agreed to acquire IsoPlexis Corp (NASDAQ: ISO) in an all-stock transaction valued at $57.8 million.
  • The combined company, which will be named PhenomeX, will be an operating cell biology company that provides live cell biology research tools.
  • Under the terms of the agreement, IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold.
  • Following the close of the transaction, Berkeley Lights shareholders will own approximately 75.2% of the combined company, and IsoPlexis shareholders will own approximately 24.8%.
  • Siddhartha Kadia will serve as CEO and a member of the combined company's Board of Directors; and
  • Sean Mackay is expected to be appointed chief product officer of the combined company.
  • The combined company anticipates delivering cost synergies of approximately $70 million annualized by 2024. The new company is expected to generate a positive operating cash flow of $150 million in revenue by 2024.
  • The transaction is expected to close in the first quarter of 2023.
  • Price Action: ISO stock is up 62.30% at $1.12 during the premarket session on the last check Thursday. BLI stock is down 8.79% at $2.18.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.